These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 16135089)

  • 1. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
    Barghorn S; Nimmrich V; Striebinger A; Krantz C; Keller P; Janson B; Bahr M; Schmidt M; Bitner RS; Harlan J; Barlow E; Ebert U; Hillen H
    J Neurochem; 2005 Nov; 95(3):834-47. PubMed ID: 16135089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abeta-globulomers are formed independently of the fibril pathway.
    Gellermann GP; Byrnes H; Striebinger A; Ullrich K; Mueller R; Hillen H; Barghorn S
    Neurobiol Dis; 2008 May; 30(2):212-20. PubMed ID: 18353662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural characterization of a soluble amyloid beta-peptide oligomer.
    Yu L; Edalji R; Harlan JE; Holzman TF; Lopez AP; Labkovsky B; Hillen H; Barghorn S; Ebert U; Richardson PL; Miesbauer L; Solomon L; Bartley D; Walter K; Johnson RW; Hajduk PJ; Olejniczak ET
    Biochemistry; 2009 Mar; 48(9):1870-7. PubMed ID: 19216516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.
    Taylor M; Moore S; Mayes J; Parkin E; Beeg M; Canovi M; Gobbi M; Mann DM; Allsop D
    Biochemistry; 2010 Apr; 49(15):3261-72. PubMed ID: 20230062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease.
    Lorenzo A; Yuan M; Zhang Z; Paganetti PA; Sturchler-Pierrat C; Staufenbiel M; Mautino J; Vigo FS; Sommer B; Yankner BA
    Nat Neurosci; 2000 May; 3(5):460-4. PubMed ID: 10769385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin.
    Sakono M; Zako T; Ueda H; Yohda M; Maeda M
    FEBS J; 2008 Dec; 275(23):5982-93. PubMed ID: 19021772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation.
    White JA; Manelli AM; Holmberg KH; Van Eldik LJ; Ladu MJ
    Neurobiol Dis; 2005 Apr; 18(3):459-65. PubMed ID: 15755672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain.
    Ishibashi K; Tomiyama T; Nishitsuji K; Hara M; Mori H
    J Neurosci Res; 2006 Aug; 84(3):632-6. PubMed ID: 16721760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.
    Hashimoto M; Shahdat HM; Yamashita S; Katakura M; Tanabe Y; Fujiwara H; Gamoh S; Miyazawa T; Arai H; Shimada T; Shido O
    J Neurochem; 2008 Dec; 107(6):1634-46. PubMed ID: 19014387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
    Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
    J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High resolution scanning tunnelling microscopy of the beta-amyloid protein (Abeta1-40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly.
    Losic D; Martin LL; Mechler A; Aguilar MI; Small DH
    J Struct Biol; 2006 Jul; 155(1):104-10. PubMed ID: 16650774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide.
    Cerf E; Sarroukh R; Tamamizu-Kato S; Breydo L; Derclaye S; Dufrêne YF; Narayanaswami V; Goormaghtigh E; Ruysschaert JM; Raussens V
    Biochem J; 2009 Jul; 421(3):415-23. PubMed ID: 19435461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.
    Kubo T; Nishimura S; Kumagae Y; Kaneko I
    J Neurosci Res; 2002 Nov; 70(3):474-83. PubMed ID: 12391608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-beta aggregation.
    Finder VH; Glockshuber R
    Neurodegener Dis; 2007; 4(1):13-27. PubMed ID: 17429215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.
    Lafaye P; Achour I; England P; Duyckaerts C; Rougeon F
    Mol Immunol; 2009 Feb; 46(4):695-704. PubMed ID: 18930548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.